VolitionRx Q3: Going-concern doubt persists
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
VolitionRx Limited (VNRX) reported third-quarter revenue of $1,613,876, versus $627,277 a year earlier; nine-month revenue was $2,997,609 versus $1,280,350. Third-quarter operating loss narrowed to $3,334,137 from $5,100,990, while nine-month net loss was $17,826,209 compared with $17,200,488.
Cash and cash equivalents were $2,357,067 at September 30, 2026, and operating activities used $15,025,536 over nine months. VolitionRx raised $11,842,078 through its at-the-market program by selling 12,401,578 shares during the nine months; it received approximately $0.3 million in additional net ATM proceeds after quarter-end through issuance of the statements.
The company reported a $27,499,300 stockholders’ deficit and said it will need further funding. Management concluded its plans do not alleviate substantial doubt about its ability to continue as a going concern within one year. The NYSE American accepted a plan giving VolitionRx until August 6, 2027 to meet listing standards requiring at least $6.0 million in stockholders’ equity; delisting proceedings may follow if it misses the deadline or makes insufficient progress.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNine-month revenue rose to $2,997,609 from $1,280,350.
- Moderate pointThird-quarter net loss narrowed to $3,807,389 from $5,409,791.
Negative
- Major pointSubstantial doubt about going concern remains within the one-year look-forward period.
- Major pointOperating cash use was $15,025,536, up from $14,191,467.
- Moderate point. Forward-looking: it has not happened yet and may not happen.NYSE American compliance deadline is August 6, 2027; delisting proceedings may follow.
Filing Explained
Volition issued Lind 8,143,266 shares for
Key Figures
Key Terms
going concern financial
at-the-market offering program financial
deferred revenue financial
Repayment Share Price financial
embedded derivative liability financial
anti-dilutive financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did VNRX report for the nine months ended September 30, 2026?
How much cash did VNRX use in operating activities during the first nine months of 2026?
Why does VNRX say substantial doubt exists about continuing as a going concern?
By when must VNRX regain NYSE American listing compliance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For the quarterly period ended
For the transition period from _________ to ________
Commission File Number:
(Exact name of registrant as specified in its charter) |
| ||
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
|
|
|
| ||
(Address of principal executive offices) |
| (Zip Code) |
+1 (
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
|
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
As of November 5, 2026, there were
VOLITIONRX LIMITED
QUARTERLY REPORT ON FORM 10-Q
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| PAGE | |||
PART I | FINANCIAL INFORMATION |
|
| |
|
|
|
| |
Item 1. | FINANCIAL STATEMENTS (UNAUDITED) |
| 5 | |
|
|
|
| |
Item 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
| 47 | |
|
|
|
| |
Item 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
| 58 | |
|
|
|
| |
Item 4. | CONTROLS AND PROCEDURES |
| 58 | |
|
|
|
| |
PART II | OTHER INFORMATION |
|
| |
|
|
|
| |
Item 1. | LEGAL PROCEEDINGS |
| 60 | |
|
|
|
| |
Item 1A. | RISK FACTORS |
| 60 | |
|
|
|
| |
Item 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
| 60 | |
|
|
|
| |
Item 3. | DEFAULTS UPON SENIOR SECURITIES |
| 60 | |
|
|
|
| |
Item 4. | MINE SAFETY DISCLOSURES |
| 60 | |
|
|
|
| |
Item 5. | OTHER INFORMATION |
| 60 | |
|
|
|
| |
Item 6. | EXHIBITS |
| 61 | |
|
|
|
| |
SIGNATURES |
| 62 | ||
| 2 |
| Table of Contents |
Use of Terms
Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the “Company,” “VolitionRx,” “Volition,” “we,” “us,” and “our” are references to VolitionRx Limited and its wholly owned subsidiaries, Volition Global Services SRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., and its majority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.
NucleosomicsTM,, Capture-PCRTM, Nu.Q® and Capture-SeqTM and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of their respective owners.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
This Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, (this “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which statements are subject to considerable risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. We have attempted to identify forward-looking statements by using words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate(s),” “expect,” “forecast(s),” “goal,” “intend,” “may,” “plan(s),” “potential,” “project,” “seek,” “should,” “strategy,” “will,” and other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words). In particular, forward-looking statements contained in this Report, and the information and documents incorporated by reference within this Report, relate to, among other things, our predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy, including regulatory approvals, reimbursement, commercialization and market acceptance; and the timing of the introduction of our products into routine clinical use; statements concerning industry trends and industry size; statements regarding anticipated demand for our products and market opportunity, or the products of our competitors; statements relating to manufacturing forecasts, and the potential impact of our relationships with contract manufacturers, original equipment manufacturers and distributors on our business; expectations regarding licensing, distribution, milestone, royalty and grant funding arrangements; assumptions regarding the future cost and potential benefits of our research and development efforts; the effect of critical accounting policies; forecasts of our liquidity position or available cash resource and financing plans; including our ability to continue as a going concern; our ability to satisfy our debt service and convertible note repayment obligations; our plans to remediate the material weakness in our internal control over financial reporting; and statements relating to the assumptions underlying any of the foregoing. We caution you that the foregoing list may not include all of the forward-looking statements made in this Report and the information and documents incorporated by reference within this Report.
We have based our forward-looking statements on our current assumptions, expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial known and unknown risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report.
Some significant factors that may impact our estimates and forward-looking statements include, but are not limited to:
| · | Our need to raise additional capital in the future, and our ability to do so, including our ability to regain compliance with NYSE American listing standards (see Note 2); |
|
|
|
| · | Our inability to generate any significant revenues or achieve profitability; |
|
|
|
| · | Our limited product development and sales and marketing capabilities could give rise to difficulties in managing our growth; |
|
|
|
| · | Our dependence on third-party distributors; |
|
|
|
| · | Our limited experience with sales and marketing; |
|
|
|
| · | The possibility that we may not be able to continue to operate, as indicated by the “going concern” opinion from our auditors; |
|
|
|
| · | Our ability to successfully develop, manufacture, market, and sell our future products; |
|
|
|
| · | Our ability to timely obtain necessary regulatory clearances or approvals to distribute and market our future products; |
|
|
|
| · | The acceptance by the marketplace of our future products; |
|
|
|
| · | The highly competitive and rapidly changing nature of the diagnostics market; |
|
|
|
| · | Protection of our patents, intellectual property and trade secrets; |
|
|
|
| · | Our reliance on third parties to manufacture and supply our intended products, and such manufacturers’ dependence on third-party suppliers; |
|
|
|
| · | The material weaknesses in our internal control over financial reporting that we have identified; |
|
|
|
| · | Pressures related to macroeconomic and geopolitical conditions; and |
|
|
|
| · | Other risks identified elsewhere in this Report, as well as in our other filings with the Securities and Exchange Commission (the “SEC”). |
| 3 |
| Table of Contents |
For additional information, refer to the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” within this Report, as well as in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on March 31, 2026 (our “Annual Report”), and the other documents that we have filed with the SEC.
In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements.
You should read this Report in its entirety, including the documents that we file as exhibits to this Report and the documents we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections.
| 4 |
| Table of Contents |
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
| Page |
|
|
Condensed Consolidated Balance Sheets | 6 |
|
|
Condensed Consolidated Statements of Operations and Comprehensive Loss | 7 |
|
|
Condensed Consolidated Statements of Stockholders’ Deficit | 8 |
|
|
Condensed Consolidated Statements of Cash Flows | 10 |
|
|
Notes to the Condensed Consolidated Financial Statements | 11 |
| 5 |
| Table of Contents |
VOLITIONRX LIMITED
Condensed Consolidated Balance Sheets
(Expressed in United States Dollars, except share numbers)
|
| September 30, |
|
| December 31, |
| ||
|
| 2026 |
|
| 2025 |
| ||
|
| $ |
|
| $ |
| ||
ASSETS |
| (UNAUDITED) |
|
|
| |||
Current Assets |
|
|
|
|
|
| ||
Cash and cash equivalents |
|
|
|
|
|
| ||
Accounts receivable |
|
|
|
|
|
| ||
Prepaid expenses |
|
|
|
|
|
| ||
Other current assets |
|
|
|
|
|
| ||
Total Current Assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
|
|
|
| ||
Operating lease right-of-use assets |
|
|
|
|
|
| ||
Intangible assets, net |
|
|
|
|
|
| ||
Total Assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' DEFICIT |
|
| ||||||
|
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
|
|
|
|
| ||
Accrued liabilities |
|
|
|
|
|
| ||
Deferred revenue |
|
|
|
|
|
| ||
Management and directors’ fees payable |
|
|
|
|
|
| ||
Current portion of long-term debt |
|
|
|
|
|
| ||
Current portion of finance lease liabilities |
|
|
|
|
|
| ||
Current portion of operating lease liabilities |
|
|
|
|
|
| ||
Current portion of grant repayable |
|
|
|
|
|
| ||
Warrant liability |
|
|
|
|
|
| ||
Derivative liability |
|
|
|
|
|
| ||
Current portion of convertible note payable, net |
|
|
|
|
|
| ||
Total Current Liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Long-term debt, net of current portion |
|
|
|
|
|
| ||
Deferred revenue, net of current portion |
|
|
|
|
|
| ||
Finance lease liabilities, net of current portion |
|
|
|
|
|
| ||
Operating lease liabilities, net of current portion |
|
|
|
|
|
| ||
Grant repayable, net of current portion |
|
|
|
|
|
| ||
Convertible note payable, net of current portion |
|
|
|
|
|
| ||
Total Long-Term Liabilities |
|
|
|
|
|
| ||
Total Liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Stockholders' Deficit |
|
|
|
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
Authorized: |
|
|
|
|
|
|
|
|
Issued and outstanding: |
|
|
|
|
|
| ||
Additional paid-in capital |
|
|
|
|
|
| ||
Accumulated other comprehensive loss |
|
| ( | ) |
|
| ( | ) |
Accumulated deficit |
|
| ( | ) |
|
| ( | ) |
Total VolitionRx limited Stockholders' Deficit |
|
| ( | ) |
|
| ( | ) |
Non-controlling interest |
|
| ( | ) |
|
| ( | ) |
Total Stockholders’ Deficit |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders’ Deficit |
|
|
|
|
|
| ||
(The accompanying notes are an integral part of these condensed consolidated financial statements)
| 6 |
| Table of Contents |
VOLITIONRX LIMITED
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(Expressed in United States Dollars, except share numbers)
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Services |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Product |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total Revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
|
|
|
|
|
| ||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Sales and marketing |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Operating Loss |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expenses) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant income |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Gain on disposal of fixed assets |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest expense |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Amortization of debt discount |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Gain (loss) on change in fair value of derivative liability |
|
|
|
|
|
|
|
| ( | ) |
|
|
| |||
Gain (loss) on change in fair value of warrant liability |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Loss on extinguishment of debt |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
Total Other Expenses |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Net Loss |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Net Loss Attributable to Non-Controlling Interest |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net Loss Attributable to VolitionRx Limited Stockholders |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Comprehensive Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Net Comprehensive Loss |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Net Loss Attributable to VolitionRx Limited Stockholders |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Deemed dividend – down round provision in warrants |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
Net Loss Attributable to Common Stockholders |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss Per Share – Basic and Diluted Attributable to VolitionRx Limited |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
– Basic and Diluted |
|
|
|
|
|
|
|
|
|
|
|
| ||||
(The accompanying notes are an integral part of these condensed consolidated financial statements)
| 7 |
| Table of Contents |
VOLITIONRX LIMITED
Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited)
(Expressed in United States Dollars, except share numbers)
For the Three and Nine Months ended September 30, 2026 and September 30, 2025 | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
| Accumulated |
|
|
|
|
|
|
| |||||||||||||
|
|
|
|
|
| Additional |
|
| Other |
|
|
|
| Non - |
|
|
| |||||||||||
|
| Common Stock |
|
| Paid-in |
|
| Comprehensive |
|
| Accumulated |
|
| Controlling |
|
|
| |||||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Income |
|
| Deficit |
|
| Interest |
|
| Total |
| |||||||
|
| # |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||
Balance, December 31, 2025 |
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Common stock issued for settlement of RSUs |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of warrants in connection with convertible note offering |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Fair value of convertible note settlement |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Common stock issued for settlement of convertible note repayments |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Tax withholdings paid related to stock-based compensation |
|
| - |
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||
Foreign currency translation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net loss for the period |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
Balance, March 31, 2026 |
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Deemed dividend - down round provision in warrants |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| |||||
Common stock issued for settlement of RSUs |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Fair value of convertible note settlement |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Common stock issued for settlement of Convertible note repayments |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Tax withholdings paid related to stock-based compensation |
|
| - |
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||
Foreign currency translation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net loss for the period |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balance, June 30, 2026 |
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Deemed dividend – down round provision in warrants |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| |||||
Common stock issued for settlement of RSUs |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Fair value of convertible note settlement |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Common stock issued for settlement of Convertible note repayments |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Foreign currency translation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss for the period |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
Balance, September 30, 2026 |
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
(The accompanying notes are an integral part of these condensed consolidated financial statements)
| 8 |
| Table of Contents |
VOLITIONRX LIMITED
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(Expressed in United States Dollars, except share numbers)
|
| Common Stock |
|
| Additional Paid-in |
|
| Accumulated Other Comprehensive Income |
|
| Accumulated |
|
| Non - Controlling |
|
|
|
| ||||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| (Loss) |
|
| Deficit |
|
| Interest |
|
| Total |
| |||||||
|
| # |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||
Balance, December 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | ||||
Common stock issued for cash, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Common stock issued for settlement of RSUs |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation in relation to modification of options |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Tax withholdings paid related to stock-based compensation |
|
| - |
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||
Foreign currency translation |
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
| ( | ) | ||||
Net loss for the period |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
Balance, March 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Common stock issued for settlement of RSUs |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Common stock issued for cash, in respect of warrant shares |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of warrants in connection with convertible note offering |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Tax withholdings paid related to stock-based compensation |
|
| - |
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||
Foreign currency translation |
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
| ( | ) | ||||
Net loss for the period |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
Balance, June 30, 2025 |
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Common stock issued for cash, in respect of warrant shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Common stock issued for settlement of RSUs |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Stock-based compensation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Tax withholdings paid related to stock-based compensation |
|
| - |
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||
Foreign currency translation |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Net loss for the period |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | ||
Balance, September 30, 2025 |
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |||
(The accompanying notes are an integral part of these condensed consolidated financial statements)
| 9 |
| Table of Contents |
VOLITIONRX LIMITED
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Expressed in United States Dollars)
|
| Nine Months Ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
|
| $ |
|
| $ |
| ||
Operating Activities |
|
|
|
|
|
| ||
Net loss |
|
| ( | ) |
|
| ( | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
| ||
Amortization of operating lease right-of-use assets |
|
|
|
|
|
| ||
(Gain) loss on disposal of fixed assets |
|
| ( | ) |
|
|
| |
Amortization of debt discount |
|
|
|
|
|
| ||
Stock-based compensation |
|
|
|
|
|
| ||
Loss on extinguishment of debt |
|
|
|
|
|
| ||
(Gain) loss on change in warrant liability |
|
| ( | ) |
|
|
| |
Loss (gain) on change in fair value of derivative liability |
|
|
|
|
| ( | ) | |
Mandatory default amount on convertible notes payable |
|
|
|
|
|
| ||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Prepaid expenses |
|
|
|
|
| ( | ) | |
Accounts receivable |
|
|
|
|
| ( | ) | |
Other current assets |
|
| ( | ) |
|
| ( | ) |
Deferred revenue, current and non-current |
|
| ( | ) |
|
| ( | ) |
Accounts payable and accrued liabilities |
|
| ( | ) |
|
|
| |
Management and directors’ fees payable |
|
|
|
|
|
| ||
Right-of-use assets operating leases liabilities |
|
| ( | ) |
|
| ( | ) |
Net Cash Used In Operating Activities |
|
| ( | ) |
|
| ( | ) |
Investing Activities |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
| ( | ) |
|
| ( | ) |
Net Cash Used In Investing Activities |
|
| ( | ) |
|
| ( | ) |
Financing Activities |
|
|
|
|
|
|
|
|
Net proceeds from issuances of common shares |
|
|
|
|
|
| ||
Tax withholdings paid related to stock-based compensation |
|
| ( | ) |
|
| ( | ) |
Proceeds from grants repayable |
|
|
|
|
|
| ||
Net proceeds from issuances of convertible note and warrants |
|
|
|
|
|
| ||
Proceeds from long-term debt |
|
|
|
|
|
| ||
Payments on long-term debt |
|
| ( | ) |
|
| ( | ) |
Payments on grants repayable |
|
| ( | ) |
|
|
| |
Payments on convertible loan note |
|
| ( | ) |
|
|
| |
Payments on finance lease obligations |
|
| ( | ) |
|
| ( | ) |
Net Cash Provided By Financing Activities |
|
|
|
|
|
| ||
Effect of foreign exchange on cash |
|
| ( | ) |
|
|
| |
Net change in cash and cash equivalents |
|
|
|
|
| ( | ) | |
Cash and cash equivalents – Beginning of the Period |
|
|
|
|
|
| ||
Cash and cash equivalents – End of the Period |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Cash Flow Information |
|
|
|
|
|
|
|
|
Interest paid |
|
|
|
|
|
| ||
Non-Cash Financing Activities |
|
|
|
|
|
|
|
|
Deemed dividend - down round provision in warrants |
|
|
|
|
|
| ||
Common stock issued upon settlement of vested RSUs |
|
|
|
|
|
| ||
Fair value of derivative liability recognized upon issuance of convertible note |
|
|
|
|
|
| ||
Issuance of warrants in connection with convertible note offering |
|
|
|
|
|
| ||
Debt issuance costs recognized upon issuance of convertible note |
|
|
|
|
|
| ||
Common stock issued for settlement of convertible note repayments |
|
|
|
|
|
| ||
Offering costs from issuance of common stock |
|
|
|
|
|
| ||
Non-cash note payable |
|
|
|
|
|
| ||
(The accompanying notes are an integral part of these condensed consolidated financial statements)
| 10 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and use of estimates
The accompanying unaudited condensed consolidated financial statements of VolitionRx Limited (the “Company” or “VolitionRx”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2025 consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 31, 2026 (the “Annual Report”). The interim unaudited condensed consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in the Annual Report. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the nine-months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026.
The preparation of the Company's Condensed Consolidated Financial Statements requires management to make certain estimates and the assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported and reported amounts of revenues and expenses. Such estimates include impairment of long-lived assets, accounts receivable, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, fair value measurements of warrant and derivative liabilities, debt discounts, and going concern assessments among others. These estimates and assumptions are based on management’s judgment. Estimates and underlying assumptions are reviewed on an ongoing basis. Changes in accounting estimates may be necessary if there are changes in the circumstances or experiences on which the estimate was based or as a result of new information. Changes in estimates, including those resulting from changes in the economic environment, are reflected in the period in which the change in estimate occurs.
Recently Issued Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which requires disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization included in each relevant expense caption presented on the statement of operations. The standard also requires a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as the total amount of selling expenses and an entity’s definition of selling expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact ASU 2024-03 will have on its condensed consolidated financial statements.
| 11 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies
Recently Issued Accounting Pronouncements (continued)
In December 2025, the FASB issued ASU 2025-10, “Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities,” which establishes authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants. Under ASU 2025-10, government grants are recognized when it is probable that the entity will both comply with the conditions of the grant and the grant will be received. The ASU provides specific accounting models for grants related to assets and grants related to income, including options to recognize government grants as deferred income or as a reduction of the asset’s cost basis. The ASU also requires enhanced disclosures regarding the nature of government grants, significant terms and conditions, accounting policies applied, and amounts recognized in the financial statements. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact ASU 2025-10 will have on its condensed consolidated financial statements.
In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements.” ASU 2025-11 clarifies and improves existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity’s financial condition or results of operations. The ASU does not introduce significant changes to recognition or measurement guidance. The amendments in ASU 2025-11 are effective for interim reporting periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2025-11 allows for either a prospective or retrospective approach on adoption. The Company is currently evaluating the impact ASU 2025-11 will have on its condensed consolidated financial statements.
The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its condensed consolidated financial statements.
Revenue Recognition
The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers.” Under ASC 606, the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).
The Company generates product revenues from the sale of its Nu.Q® Vet Cancer Test, from the sale of nucleosomes, and from the sale of research use only kits. In addition, revenue is received from external third parties for services the Company performs for them in its laboratory.
Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:
Royalty
The Company receives royalty revenue on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under “Royalty” in the consolidated statements of operations and comprehensive loss. The Company has not recognized any revenue under royalty for the years ended December 31, 2025, and December 31, 2024. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these amounts based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known.
Product
The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in “Product” in the consolidated statements of operations and comprehensive loss.
| 12 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)
Revenue Recognition (continued)
Service
The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties under “Service” under the consolidated statements of operations.
For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.
Licensing
The Company includes revenue recognized from the licensing of certain rights to third parties in “Licensing” in the consolidated statements of operations and comprehensive loss. For each licensing, development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.
| 13 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)
Revenue Recognition (continued)
Revenue from Heska Agreement
On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the “License Agreement”) with Heska Corporation (“Heska”), now an Antech company, a leading global provider of advanced veterinary diagnostics, pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q® Vet Cancer Test at the point of care (“POC”) initially for the screening of lymphoma and hemangiosarcoma in dogs (“Canine Lymphoma & HSA”), and non-exclusive rights to sell its Nu.Q® Vet Cancer Test in kit format (“Kits”) through Heska’s network of central reference laboratories (“Central Lab”) initially for Canine Lymphoma & HSA.
Under and subject to the terms of the License Agreement, Belgian Volition received an upfront
Pursuant to the terms of the License Agreement, Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (“Key Components”) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska’s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs.
The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of
According to ASC Topic 606, “Revenue from Contracts with Customers”, a performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.
In conjunction with the License Agreement, the Company evaluated whether the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract.
During the first quarter of 2022, the Company received a $
In determining the transaction price, the Company analyzed the variable consideration and whether such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract represents a significant judgment in recognizing revenue.
Deferred Revenue (Contract Liabilities) and Contract Assets
Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of September 30, 2026, the Company recorded $
| 14 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)
Fair Value Measurements
Pursuant to ASC 820, “Fair Value Measurements and Disclosures,” an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:
Level 1
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
The financial instruments of the Company consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, a warrant liability and derivative liabilities. The carrying amounts of these items approximate fair value due to their short-term nature and their market interest rates, except for the warrant liability and derivative liabilities, which are recorded at fair value at the end of each reporting period. The derivative liability related to the 2026 Lind Note was classified within Level 2 of the fair value hierarchy as of September 30, 2026.
Included in the following table are the Company’s major categories of assets and liabilities measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025.
Fair Value Measurements at September 30, 2026 |
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
| ||||||||
Description |
| Level 1 |
|
| Level 2 |
|
| Level 3 |
|
| Total |
| ||||
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Derivative liability May 2025 |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Derivative liability January 2026 |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Fair Value Measurements at December 31, 2025 |
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
| ||||||||
Description |
| Level 1 |
|
| Level 2 |
|
| Level 3 |
|
| Total |
| ||||
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Derivative liability May 2025 |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
| 15 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)
Fair Value Measurements (continued)
As of September 30, 2026, the warrant liability was $
Warrant Liability |
|
| ||
|
| Total |
| |
|
| $ |
| |
Balance at December 31, 2024 |
|
|
| |
Gain on change in fair value of warrant liability |
|
| ( | ) |
Balance at December 31, 2025 |
|
|
| |
Gain on change in fair value of warrant liability |
|
| ( | ) |
Balance at September 30, 2026 |
|
|
| |
As of September 30, 2026, the derivative liability related to the 2025 Lind Note (as defined below) was $
Derivative Liability - 2025 Lind Note |
|
| ||
|
| Total |
| |
|
| $ |
| |
Balance at December 31, 2024 |
|
|
| |
Initial fair value of embedded derivative liability upon issuance of convertible note |
|
|
| |
Gain on change in fair value of derivative liability |
|
| ( | ) |
Balance at December 31, 2025 |
|
|
| |
Loss on change in fair value of derivative liability |
|
|
| |
Extinguishment upon settlement |
|
| ( | ) |
Balance at September 30, 2026 |
|
|
| |
As of September 30, 2026, the derivative liability related to the 2026 Lind Note (as defined below) was $
Derivative Liability - 2026 Lind Note |
|
| ||
|
| Total |
| |
|
| $ |
| |
Initial fair value of embedded derivative liability upon issuance of convertible note |
|
|
| |
Loss on change in fair value of derivative liability |
|
|
| |
Extinguishment upon settlement |
|
| ( | ) |
Balance at September 30, 2026 |
|
|
| |
| 16 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)
Basic and Diluted Net Loss Per Share
The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share,” which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. For all periods presented, basic and diluted net loss per share and weighted average shares outstanding have been retrospectively adjusted to reflect the reverse stock split described below. As of September 30, 2026,
Reverse stock split
In April 2026, following stockholder approval, the Company effected a one-for-twenty reverse stock split of its issued and outstanding common stock, par value $0.001 per share (the “Reverse Stock Split”). On April 27, 2026, the Company filed a Certificate of Third Amendment to its Second Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to effect the Reverse Stock Split, which became effective at 12:01 a.m. Eastern Time on April 28, 2026. The Company’s common stock began trading on a post-split basis on April 28, 2026. As a result of the Reverse Stock Split, every twenty shares of the Company’s issued and outstanding common stock were automatically converted into one share of common stock. No fractional shares were issued in connection with the Reverse Stock Split, and each stockholder who otherwise would have been entitled to receive a fractional share received one whole share of common stock in lieu of such fractional share. Accordingly, all share and per-share amounts for all periods presented in these Condensed Consolidated Financial Statements and accompanying notes have been retroactively adjusted to reflect the Reverse Stock Split. In addition, all outstanding equity awards, warrants, convertible notes and other equity securities and instruments outstanding immediately prior to the Reverse Stock Split have been proportionately adjusted to reflect the Reverse Stock Split, to the extent required by their respective terms.
| 17 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 2 - Liquidity and Going Concern Assessment
The Company's condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. Management assesses liquidity and going concern uncertainty in the Company’s consolidated financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings under financing arrangements, to operate for a period of at least one year from the date the financial statements are issued, which is referred to as the “look-forward period,” as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management considered various scenarios, forecasts, projections, estimates and made certain key assumptions, including the timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs, its expected debt service and convertible note repayment obligations, and its ability to raise additional capital, if necessary, among other factors.
For the nine-months ended September 30, 2026, the Company incurred a net loss of $
Subsequent to September 30, 2026, and through the date these condensed consolidated financial statements were issued, the Company received net proceeds of approximately $
The Company has generated operating losses and has experienced negative cash flows from operations since inception. The Company has not generated significant revenues and expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. The future of the Company as an operating business will depend on its ability to obtain sufficient capital through equity or debt financings, licensing or distribution arrangements, or other strategic transactions and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front milestones, royalty, or other payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner. Management continues to exercise tight cost controls to conserve cash. As part of the Company’s cash conservation efforts, directors and certain employees have elected to exchange a portion of their fees earned or paid in cash or salary, respectively, for RSUs in the Company for a period of up to twelve months.
On February 6, 2026, the Company received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $
The Company was required to submit a plan to the NYSE American by March 8, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. The Company submitted a plan prior to the deadline.
On April 22, 2026, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Company’s previously submitted plan to regain compliance with the NYSE American’s listing standards (the “Plan”) was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 6, 2027 (the “Plan Period”) to regain compliance with the continued listing standards.
During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by August 6, 2027, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.
| 18 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
The Acceptance Letter has no immediate impact on the listing of the Company’s shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Company’s common stock will continue to trade under the symbol “VNRX”. The Acceptance Letter does not affect the Company’s ongoing business operations or its reporting requirements with the SEC.
The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and to eventually attain profitable operations.
Management assessed the mitigating effect of these plans to determine if it is probable that the plans would be effectively implemented within one year after the condensed consolidated financial statements are issued and when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of the Company’s plans will result in the necessary funding to continue current operations and satisfy current and expected debt obligations. The Company has implemented short-term cash preservation and cost-saving initiatives to conserve cash. Although the Company has raised additional capital subsequent to September 30, 2026, management expects that additional funding will be required to continue current operations and satisfy current and expected obligations during the look-forward period. The Company concluded that these plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.
The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.
| 19 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 3 - Property and Equipment
The Company’s property and equipment consisted of the following amounts as of September 30, 2026 and December 31, 2025:
|
|
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| Useful Life |
| Cost $ |
|
| Cost $ |
| ||
Computer hardware and software |
|
|
|
|
|
|
| |||
Laboratory equipment |
|
|
|
|
|
|
| |||
Office furniture and equipment |
|
|
|
|
|
|
| |||
Buildings |
|
|
|
|
|
|
| |||
Building improvements |
|
|
|
|
|
|
| |||
Land |
| Not amortized |
|
|
|
|
|
| ||
Total property and equipment |
|
|
|
|
|
|
|
| ||
Less accumulated depreciation |
|
|
|
|
|
|
|
| ||
Total property and equipment, net |
|
|
|
|
|
|
|
| ||
During the nine-months period ended September 30, 2026 and September 30, 2025, the Company recognized $
| 20 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 4 - Intangible Assets
The Company’s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years.
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| Cost $ |
|
| Cost $ |
| ||
Patents and Licenses |
|
|
|
|
|
| ||
Total Patents and Licenses |
|
|
|
|
|
| ||
Less accumulated amortization |
|
|
|
|
|
| ||
Total Patents and Licenses, net |
|
|
|
|
|
| ||
During the nine-months period ended September 30, 2026 and September 30, 2025, the Company recognized $
The Company amortizes the patents and licenses on a straight-line basis with terms ranging from
2026 - Remaining |
| $ |
| |
2027 |
| $ |
| |
2028 |
| $ |
| |
2029 |
| $ |
| |
2030 |
| $ |
| |
Greater than 5 years |
| $ |
| |
Total Intangible Assets |
| $ |
|
The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360, “Property, Plant and Equipment,” as of December 31, 2025. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2025.
Note 5 - Related-Party Transactions
See Note 6, Common Stock, for common stock issued to related parties and Note 7, Stock-Based Compensation, for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of consultancy services which are accrued under management and directors’ fees payable (see condensed consolidated balance sheets).
| 21 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock
As of September 30, 2026, the Company was authorized to issue
Stock Option Exercises
During the nine-months ended September 30, 2026, no shares of common stock were issued pursuant to the exercise of stock options.
Stock Options Expired / Cancelled
Below is a table summarizing the stock options that expired during the nine-months ended September 30, 2026, all of which were issued pursuant to the 2015 Plan.
Equity Incentive Plan |
| Options (#) |
|
| Grant Date |
| Options Cancelled (#) |
|
| Grant Price ($) |
|
| Cancellation Date | ||||
2015 |
|
|
|
| |
|
|
|
|
|
|
| | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
RSU Settlements
Below is a table summarizing the RSUs that vested and settled during the nine-months ended September 30, 2026, all of which were issued pursuant to the 2015 Plan.
Equity Incentive Plan |
| RSUs Vested (#) |
|
| Vest Date |
| Shares Issued (#) |
|
| Shares Withheld for Taxes (#) |
| |||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
| |
|
|
|
|
|
| ||||
|
|
|
| |
|
|
|
|
|
| ||||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
| |
|
|
|
|
|
| ||||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
| |
|
|
|
|
|
| ||||
|
|
|
| |
|
|
|
|
| - |
| |||
|
|
|
|
|
|
|
|
|
|
|
| |||
Below is a table summarizing the RSUs that vested and settled during the nine-months ended September 30, 2026, all of which were issued pursuant to the 2024 Plan.
Equity Incentive Plan |
| RSUs Vested (#) |
|
| Vest Date |
| Shares Issued (#) |
|
| Shares Withheld for Taxes (#) |
| |||
|
|
|
| |
|
|
|
|
|
| ||||
|
|
|
| |
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
| |||
| 22 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock (continued)
2026 Lind Purchase Agreement
On January 7, 2026, the Company entered into an amended and restated securities purchase agreement (the “Amended SPA”) with Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”). Under the Amended SPA, the Company received $
On May 15, 2025, the Company and Lind entered into a securities purchase agreement (the “Original SPA”) pursuant to which the Company issued to Lind a senior secured convertible promissory note in the principal amount of $
The 2026 Lind Note, which does not accrue interest, is repayable in
The 2026 Lind Note may be converted by Lind from time to time at a price of $
Issuance of shares of common stock upon repayment or conversion of the Lind Notes (the “Note Shares”) and upon exercise of the Lind Warrants (the “Warrant Shares”) is subject to an
| 23 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock (continued)
2026 Lind Purchase Agreement (continued)
Upon the occurrence of any Event of Default (as defined in the 2026 Lind Note), the 2026 Lind Note will become immediately due and payable and the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the 2026 Lind Note, subject to a reduction to 110% in certain circumstances, in addition to any other remedies under the 2026 Lind Note or the other transaction documents. Events of Default include, among others, failure of the Company to make any 2026 Lind Note payment when due, a default in any indebtedness or adverse judgments in excess of threshold amounts, the failure of the Company to instruct its transfer agent to issue unlegended certificates in certain circumstances, the Company’s shares of common stock no longer being publicly traded or listed on a national securities exchange, any stop order or trading suspension restricting the trading in the Company’s common stock for a specified period, the announcement or consummation of a Change of Control (as defined in the Amended SPA), the failure to file reports or filings required by the SEC, and the Company’s market capitalization falling below a threshold amount for a specified period, each as defined in the 2026 Lind Note.
As a result of the Company’s failure to comply with the market capitalization covenant, on May 21, 2026, the Company and Lind entered into a waiver and consent (the “Waiver”) pursuant to which Lind waived certain rights and remedies under the Lind Notes and the other transaction documents arising from the Company’s failure to comply with the market capitalization covenant, subject to the terms and conditions set forth in the Waiver. Accordingly, Lind has waived and is no longer entitled to exercise any rights or remedies arising from the Company’s failure to comply with the market capitalization covenant now or in the future, except those rights and remedies set forth in the Lind Notes which are expressly preserved in the Waiver. In particular, Lind waived its rights under the Lind Notes to declare any amounts due and payable, demand immediate payment in full, accelerate obligations or foreclose upon any collateral as a result of the failure to comply with the market capitalization covenant now or in the future.
The Company’s failure to comply with the market capitalization covenant resulted in the imposition of an additional amount payable under the Lind Notes in an amount equal to 10% of the outstanding principal amount of each Note as provided by the terms of the Lind Notes. Pursuant to the Waiver and in accordance with the terms of the Lind Notes, Lind may demand that all or a portion of the outstanding principal amount of either Note be converted into shares of the Company’s common stock at the lower of (i) the then-current Conversion Price under the applicable Note, and (ii) 90% of the average of the three lowest VWAPs during the 20 trading days prior to the delivery by Lind of the applicable notice of conversion; provided that such conversion does not result in a violation of the beneficial ownership limitations set forth in the Lind Notes.
The 2026 Lind Note contains certain negative covenants, including restricting the Company from certain distributions, stock repurchases, borrowing, sale of assets, loans and exchange offers. Additionally, unless waived by Lind, the Company shall be required to utilize a portion of the proceeds from certain specified debt or equity transactions and asset sales to repay the outstanding principal amount due under the 2026 Lind Note.
2026 Maxim Purchase Agreement
On June 7, 2026, the Company entered into a securities purchase agreement (the “Maxim Purchase Agreement”) with Maxim Group LLC, in connection with the Company’s offer of an aggregate of
| 24 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock (continued)
2026 Maxim Purchase Agreement (continued)
The Maxim Warrants have an exercise price of $
The net proceeds to the Company from the Maxim Offering were approximately $
2025 Equity Capital Raise
On March 24, 2025, the Company entered into a securities purchase agreement with the several purchasers, pursuant to which the Company issued and sold to such purchasers, in a registered direct offering pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259783) declared effective by the SEC on November 8, 2021 (the “2021 Form S-3”), an aggregate of
August 2025 Registered Direct Offering
On August 4, 2025, the Company entered into a securities purchase agreement with the several purchasers party thereto, pursuant to which the Company issued and sold to such purchasers, in a registered direct offering pursuant to Company’s registration statement on Form S-3 (Reg. No. 333-283088) filed with the SEC on November 8, 2024, as amended on April 11, 2025, and declared effective by the SEC on April 18, 2025 (the “2025 Form S-3”), an aggregate of
| 25 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock (continued)
September 2025 Private Placement
On September 18, 2025, the Company entered into a securities purchase agreement with an existing stockholder, pursuant to which the Company issued and sold to such purchaser
October 2025 Underwritten Offering
Initial Closing
On October 10, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), pursuant to which the Company issued and sold to the underwriter in an underwritten public offering pursuant to the 2025 Form S-3, at the initial closing,
The Warrants have an exercise price of $
| 26 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock (continued)
October 2025 Underwritten Offering (continued)
Initial Closing (continued)
Certain directors and officers agreed to purchase an aggregate of
Net proceeds to the Company from the initial closing of the Offering were approximately $
Pursuant to the Underwriting Agreement, in connection with the initial closing of the Offering on October 14, 2025, the Company reimbursed the Underwriter for $
Overallotment Closing
On November 7, 2025, the Company and the Underwriter entered into an amendment to the Underwriting Agreement (the “Amendment”) to modify the terms of the Over-Allotment Option to permit the Underwriter, in its sole discretion, to exercise the Over-Allotment Option with respect to solely Option Shares, solely Option Warrants, or any combination thereof, rather than only as a combined exercise for both Option Shares and Option Warrants together. Concurrently with the execution of the Amendment, the Underwriter exercised its Over-Allotment Option to purchase
In connection with the Underwriter’s exercise of the Over-Allotment Option and pursuant to the Underwriting Agreement, the Company also issued to the Underwriter (and certain of its designees) warrants to purchase up to an aggregate
| 27 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 6 - Common Stock (continued)
Shares Issued in Repayment of Convertible Notes
During the nine-months ended September 30, 2026, the Company issued an aggregate of
During the nine-months ended September 30, 2026, the Company also issued an aggregate of
Refer to Note 8 – Commitments and Contingencies—Convertible Note Payable, for additional information regarding the Company’s outstanding convertible notes, and Note 9 – Subsequent Events, for information regarding share issuances in repayment of the 2026 Lind Note made subsequent to September 30, 2026.
2025 ATM Sales Agreement
On April 22, 2025, the Company entered into a Capital On DemandTM Sales Agreement (the "2025 ATM Sales Agreement") with JonesTrading Institutional Services, LLC ("JonesTrading") to sell shares of the Company's common stock, with an aggregate offering price of up to $
| 28 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation
a) Warrants
The following table summarizes the changes in warrants of the Company outstanding during the nine-months period ended September 30, 2026.
|
| Number of Warrants |
|
| Weighted Average Exercise Price ($) |
| ||
Outstanding at December 31, 2025 |
|
|
|
|
|
| ||
Granted |
|
|
|
|
|
| ||
Expired/Cancelled |
|
| ( | ) |
|
|
| |
Outstanding at September 30, 2026 |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Exercisable at September 30, 2026 |
|
|
|
|
|
| ||
Below is a table summarizing the warrants issued and outstanding as of September 30, 2026, which have an aggregate weighted average remaining contractual life of
Number Outstanding |
|
| Number Exercisable |
|
| Exercise Price ($) |
|
| Weighted Average Remaining Contractual Life (Years) |
|
| Proceeds to Company if Exercised ($) |
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 29 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
a) Warrants (continued)
Warrants Granted
2026
On January 7, 2026, in connection with the 2026 Lind note, the Company issued the 2026 Lind Warrant for the purchase of up to 350,018 shares of our
On June 7, 2026, the Company entered into the Maxim Purchase Agreement in connection with the Maxim Offering of
The Maxim Warrants have an exercise price of $
The additional gross proceeds to the Company from the exercise of the Maxim Warrants, if fully exercised on a cash basis, will be approximately $
Warrants Cancelled
2026
During the period
Stock-based compensation expense related to warrants of $nil and $nil was recorded in the nine-months ended September 30, 2026 and September 30, 2025, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $nil. As of September 30, 2026, the total intrinsic value of warrants outstanding was $nil.
| 30 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
a) Warrants (continued)
Exercise Price Adjustments
2026
On June 9, 2026, as a result of the sale of
On August 28, 2026, as a result of sales of common stock under the 2025 ATM Sales Agreement at prices below the then-applicable exercise price, the exercise price of the outstanding warrants issued to Lind was further reduced pursuant to the down-round provisions contained in those warrants from $
The Lind Warrants are classified within stockholders’ equity. In accordance with ASC 260-10, the Company measured the effect of each triggered down-round feature as the difference between the fair value of the warrants immediately before and immediately after the applicable reduction in exercise price. The June 2026 exercise price reduction resulted in incremental value of $
b) Options
The following table summarizes the changes in options outstanding of the Company during the three-month period ended September 30, 2026, all of which were issued pursuant to the 2015 Plan.
|
| Number of Options |
|
| Weighted Average Exercise Price ($) |
| ||
Outstanding at December 31, 2025 |
|
|
|
|
|
| ||
Expired/Cancelled |
|
| ( | ) |
|
|
| |
Outstanding at September 30, 2026 |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Exercisable at September 30, 2026 |
|
|
|
|
|
| ||
| 31 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
b) Options (continued)
Below is a table summarizing the options issued and outstanding as of September 30, 2026, all of which were issued pursuant to the 2015 Plan and which have an aggregate weighted average remaining contractual life of
Number Outstanding |
|
| Number Exercisable |
|
| Exercise Price ($) |
|
| Weighted Average Remaining Contractual Life (Years) |
|
| Proceeds to Company if Exercised ($) |
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Below is a table summarizing the options that were forfeited during the nine-months ended September 30, 2026, all of which were issued pursuant to the 2015 Plan.
Equity Incentive Plan |
| Options (#) |
|
| Grant Date |
| Options Cancelled (#) |
|
| Grant Price ($) |
|
| Cancellation Date | ||||
2015 |
|
|
|
| |
|
|
|
|
|
|
| | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Stock-based compensation expense related to stock options of $nil and $nil was recorded in the nine-months ended September 30, 2026 and September 30, 2025, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $nil. As of September 30, 2026, the total intrinsic value of stock options outstanding was $nil.
| 32 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
c) (i) Restricted Stock Units – 2015 Plan
Below is a table summarizing the RSUs issued and outstanding as of September 30, 2026, all of which were issued pursuant to the 2015 Plan.
|
| RSUs (#) |
|
| Weighted Average Grant Date Fair Value Share Price ($) |
| ||
Outstanding at December 31, 2025 |
|
|
|
|
|
| ||
Granted |
|
| - |
|
|
|
| |
Vested/Settled |
|
| ( | ) |
|
|
| |
Cancelled / Forfeited |
|
| ( | ) |
|
|
| |
Outstanding at September 30, 2026 |
|
|
|
|
|
| ||
Below is a table summarizing the RSUs issued and outstanding as of September 30, 2026, all of which were issued pursuant to the 2015 Plan and which have an aggregate weighted average remaining contractual life of
RSUs Outstanding (#) |
|
| Weighted Average Grant Date Fair Value Share Price ($) |
|
| Weighted Average Remaining Contractual Life (Years) |
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
| |
Stock-based compensation expense related to RSUs of $
| 33 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
c) (i) Restricted Stock Units – 2015 Plan (continued)
Below is a table summarizing the RSUs vested and settled during the nine-months ended September 30, 2026, all of which were issued pursuant to the 2015 Plan.
Equity Incentive Plan |
| RSUs Vested (#) |
|
| Vest Date |
| Shares Issued (#) |
|
| Shares Withheld for Taxes (#) |
| |||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
2015 |
|
|
|
| |
|
|
|
|
|
| |||
2015 |
|
|
|
| |
|
|
|
|
|
| |||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
2015 |
|
|
|
| |
|
|
|
|
|
| |||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
2015 |
|
|
|
| |
|
|
|
|
|
| |||
2015 |
|
|
|
| |
|
|
|
|
| - |
| ||
|
|
|
|
|
|
|
|
|
|
|
| |||
Below is a table summarizing the RSUs cancelled during the nine-months ended September 30, 2026, all of which were originally issued pursuant to the 2015 Plan.
Equity Incentive Plan |
| RSUs (#) |
|
| Cancellation Date |
| Vesting Date |
| RSUs Cancelled (#) |
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
2015 |
|
|
|
| |
| |
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| ||
| 34 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
c) (ii) Restricted Stock Units – 2024 Plan
Below is a table summarizing the RSUs issued and outstanding as of September 30, 2026, all of which were issued pursuant to the 2024 Plan.
|
| RSUs (#) |
|
| Weighted Average Grant Date Fair Value Share Price ($) |
| ||
Outstanding at December 31, 2025 |
|
|
|
|
|
| ||
Granted |
|
|
|
|
|
| ||
Vested/Settled |
|
| ( | ) |
|
|
| |
Cancelled / Forfeited |
|
| ( | ) |
|
|
| |
Outstanding at September 30, 2026 |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Exercisable at September 30, 2026 |
|
| - |
|
|
|
| |
Below is a table summarizing the RSUs issued and outstanding as of September 30, 2026, all of which were issued pursuant to the 2024 Plan and which have an aggregate weighted average remaining contractual life of
RSUs Outstanding (#) |
|
| Weighted Average Grant Date Fair Value Share Price ($) |
|
| Weighted Average Remaining Contractual Life (Years) |
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
| |
Below is a table summarizing the RSUs granted during the nine-months ended September 30, 2026, all of which were issued pursuant to the 2024 Plan. The RSUs vest equally over periods stated on the dates noted, subject to the recipient’s continued service to the Company, and will result in the RSU compensation expense stated.
| ||||||||||||||||||||||
Equity Incentive Plan |
| RSUs Granted (#) |
|
| Grant Date |
| Vesting Period |
| First Vesting Date |
| Second Vesting Date |
|
| Third Vesting Date |
|
| RSU Expense ($) |
| ||||
2024 |
|
|
|
| |
|
| |
|
| N/A |
|
|
| N/A |
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| 35 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 - Stock-Based Compensation (continued)
c) (ii) Restricted Stock Units – 2024 Plan (continued)
Below is a table summarizing the RSUs vested during the nine-months ended September 30, 2026, all of which were originally issued pursuant to the 2024 Plan.
| ||||||||||||||
Equity Incentive Plan |
| RSUs Vested (#) |
|
| Vest Date |
| Shares Issued (#) |
|
| Shares Withheld for Taxes (#) |
| |||
2024 |
|
|
|
| |
|
|
|
|
|
| |||
2024 |
|
|
|
| |
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
| |||
Below is a table summarizing the RSUs cancelled during the nine-months ended September 30, 2026, all of which were originally issued pursuant to the 2024 Plan.
| ||||||||||||
Equity Incentive Plan |
| RSUs (#) |
|
| Cancellation Date |
| Vesting Date |
| RSUs Cancelled (#) |
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
2024 |
|
|
|
| |
| Mar 17, 2027 |
|
|
| ||
2024 |
|
|
|
| |
| |
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| ||
As of September 30, 2026, an aggregate of
| 36 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies
a) Finance Lease Obligations
The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of September 30, 2026.
For the Nine Months Ending September 30, 2026 |
| Amount |
| |
|
| $ |
| |
2026 - Remaining |
|
|
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
2030 |
|
|
| |
Greater than 5 years |
|
|
| |
Total |
|
|
| |
Less: Amount representing interest |
|
| ( | ) |
Present value of minimum lease payments |
|
|
| |
b) Operating Lease Right-of-Use Obligations
Operating leases as of September 30, 2026, and December 31, 2025, consisted of the following:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| $ |
|
| $ |
| ||
Operating right-of-use assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Operating lease liabilities, current portion |
|
|
|
|
|
| ||
Operating lease liabilities, long term |
|
|
|
|
|
| ||
Total operating lease liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Weighted average remaining lease (months) |
|
|
|
|
|
| ||
Weighted average discount rate |
|
| % |
|
| % | ||
During the nine-months ended September 30, 2026, cash paid for amounts included for the measurement of lease liabilities was $161,506 and the Company recorded operating lease expense of $161,495.
| 37 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies
b) Operating Lease Right-of-Use Obligations (continued)
The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of September 30, 2026.
For the Nine Months Ending September 30, 2026 |
| Amount |
| |
|
| $ |
| |
2026 - Remaining |
|
|
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
Total |
|
|
| |
Less: imputed interest |
|
| ( | ) |
Total Operating Lease Liabilities |
|
|
| |
The Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the nine-months ended September 30, 2026, the Company recognized $
For the Nine Months Ending September 30, 2026 |
| Amount |
| |
|
| $ |
| |
2026 - Remaining |
|
|
| |
2027 |
|
|
| |
Total Operating Lease Liabilities |
|
|
| |
c) Grants Repayable
As of September 30, 2026, the total grant balance repayable was $
For the Nine Months Ending September 30, 2026 |
| Amount |
| |
|
| $ |
| |
2026 - Remaining |
|
|
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
2030 |
|
|
| |
Greater than 5 years |
|
|
| |
Total Grants Repayable |
|
|
| |
| 38 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
d) Long-Term Debt
As of September 30, 2026, the total balance for long-term debt payable was $
For the Nine Months Ending September 30, 2026 |
| Amount |
| |
|
| $ |
| |
2026 - Remaining |
|
|
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
2030 |
|
|
| |
Greater than 5 years |
|
|
| |
Total |
|
|
| |
Less: amount representing interest |
|
| ( | ) |
Total Long-Term Debt |
|
|
| |
In December 2025, the Company entered into a five year loan agreement with SA Namur Invest Preface for a maximum of €
In March 2026, the Company entered into a five year loan agreement with Wallonie Entreprendre for a maximum of €
e) Collaborative Agreement Obligations
In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a
In 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis for a cost to the Company of $
In July 2023, the Company entered into a research agreement with Xenetic Biosciences Inc and CLS Therapeutics Ltd to evaluate the anti-tumoral effects of Nu.Q® CAR T cells for a cost to the Company of $
In August 2023, the Company entered into a project research agreement with Guy’s and St Thomas’ NHS Foundation Trust to evaluate the practical clinical utility of the Nu.Q® H3.1 nucleosome levels in adult patients with sepsis to facilitate early diagnosis and prognostication for a cost to the Company of $
| 39 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
e) Collaborative Agreement Obligations (continued)
In October 2024, the Company entered into an agreement with the National Taiwan University to undertake a clinical research study entitled Validation of Nu.Q® biomarker panel in differentiating between high and low risk of cancer in nodules identified by Lung cancer LDCT screening for a cost to the Company of $
The Company entered into an agreement with Gustave Roussy a leading cancer centre in Europe that treats patients with all types of cancer to perform and be responsible for the co-ordination of a Non-Interventional Phase IV clinical trial to undertake a Prospective analysis of circulating nucleosomes in patients receiving a first line treatment for a non-Hodgkin lymphoma for a cost to the Company of $
As of September 30, 2026, the total amount to be paid for future research and collaboration commitments was $
|
| Total Amount Remaining |
|
| 2026 |
| ||
|
| $ |
|
| $ |
| ||
National University of Taiwan |
|
|
|
|
|
| ||
MD Anderson Cancer Center |
|
|
|
|
|
| ||
Guys and St Thomas |
|
|
|
|
|
| ||
Xenetic Biosciences |
|
|
|
|
|
| ||
National University of Taiwan |
|
|
|
|
|
| ||
Gustave Roussy |
|
|
|
|
|
| ||
Total Collaborative Obligations |
|
|
|
|
|
| ||
| 40 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
f) Convertible Notes Payable
On May 15, 2025, the Company entered into the Original SPA with Lind, pursuant to which the Company issued the 2025 Securities consisting of the 2025 Lind Note in the principal amount of $
The 2025 Lind Note, which does not accrue interest, is repayable in 18 consecutive monthly installments in the amount of $
The 2025 Lind Note may be converted by Lind from time to time at the conversion price set forth in the 2025 Lind Note (references to the “conversion price” of a Lind Note mean the conversion price applicable under such Lind Note, as adjusted from time to time). The dollar amount of any conversions by Lind will be applied toward upcoming 2025 Lind Note payments in reverse chronological order. The 2025 Lind Note may be prepaid in whole upon written notice on any business day following August 13, 2025; but in the event of a prepayment notice, Lind may convert up to one-third of the principal amount due at the lesser of the Repayment Share Price or the Conversion Price.
Issuance of “Note Shares” and “Warrant Shares” is subject to an
Upon the occurrence of any Event of Default (as defined in the 2025 Lind Note or the 2026 Lind Note, as applicable), the applicable Lind Note will become immediately due and payable and the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the applicable Lind Note, subject to a reduction to 110% in certain circumstances, in addition to any other remedies under the applicable Lind Note or the other transaction documents. Events of Default include, among others, failure of the Company to make any Lind Note payment when due, a default in any indebtedness or adverse judgments in excess of threshold amounts, the failure of the Company to instruct its transfer agent to issue unlegended certificates in certain circumstances, the Company’s shares of common stock no longer being publicly traded or listed on a national securities exchange, any stop order or trading suspension restricting the trading in the Company’s common stock for a specified period, the announcement or consummation of a Change of Control (as defined in the Original SPA or Amended SPA, as applicable), the failure to file reports or filings required by the SEC, and the Company’s market capitalization falling below a threshold amount for a specified period, each as described in the applicable Lind Note.
| 41 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
f) Convertible Notes Payable (continued)
The Lind Notes contain certain negative covenants, including restricting the Company from certain distributions, stock repurchases, borrowing, sale of assets, loans and exchange offers. Additionally, unless waived by Lind, the Company is required to utilize a portion of the net proceeds from certain specified debt or equity transactions and asset sales to repay the outstanding principal amount due under the applicable Lind Note.
As described in Note 6 – Common Stock, on January 7, 2026, the Company entered into the Amended SPA with Lind, pursuant to which the Company issued the 2026 Lind Note in the principal amount of $
The Company evaluated the embedded features within the convertible notes in accordance with ASC Topic 480 and ASC Topic 815. The Company determined that the embedded features, specifically (i) the default penalty on outstanding principal, and (ii) the default conversion option into common shares at the lower of the then-current Conversion Price and 90% of the average of the three lowest volume weighted average price’s during the 20 Trading Days prior to delivery of the applicable notice of conversion, constitute derivative. These features, arising from default provisions, including the contingent default penalty (deemed redemption) and the contingent variable conversion feature, meet the definition of a derivative and do not qualify for derivative accounting exemptions. Consequently, these embedded features were bifurcated from the debt host as derivative liabilities.
The initial fair value of the derivative liabilities was determined using a Monte Carlo simulation valuation model, considering various potential outcomes and scenarios. The model used the following assumptions:
Subsequent changes in fair value are recognized in the statement of operations for each reporting period. The issuance costs for the convertible notes, along with the allocated fair values of both the 2025 Lind Warrant and 2026 Lind Warrant and the bifurcated embedded derivative liabilities, were collectively treated as a debt discount. The debt discount is amortized to interest expense over the term of the applicable note using the effective interest method.
During the nine-months September 30, 2026, the Company issued shares of common stock to Lind in repayment of amounts due under the 2025 Lind Note. Refer to Note 6 – Common Stock, for additional information regarding shares issued during the period in repayment of the Company’s convertible notes.
During the nine-months ended September 30, 2026, the Company issued shares of common stock to Lind in repayment and conversion of amounts due under the 2025 Lind Note and the 2026 Lind Note. On September 11, 2026, the Company repaid the remaining $
| 42 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
f) Convertible Notes Payable (continued)
The Conversion Price of the 2026 Lind Note, $
Estimated future minimum principal payments of the 2026 Lind Note for the next five years consist of the following as of September 30, 2026.
For the Nine Months Ending September 30, 2026 |
| Amount |
| |
|
| $ |
| |
2026 - Remaining |
|
|
| |
2027 |
|
|
| |
Total Payments |
|
|
| |
|
|
|
|
|
Principal |
|
|
| |
Debt discount |
|
| ( | ) |
Current portion, net |
|
|
| |
|
|
|
|
|
Principal |
|
|
| |
Debt discount |
|
|
| |
Convertible note payable, net of current portion |
|
|
| |
On May 8, 2026, the Company’s market capitalization fell below $
Pursuant to the May 2026 Waiver, Lind waived its acceleration, payment-demand, and collateral-foreclosure remedies with respect to this and any future market capitalization default, except for its triggered conversion right, which was preserved (in each case as defined in the Lind Notes). The 110% mandatory default amount was not waived and remains an obligation of the Company.
| 43 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
f) Convertible Notes Payable (continued)
On September 2, 2026, the Company and Lind entered into a waiver and consent (the “September 2026 Waiver”) pursuant to which Lind consented to any and all sales of common stock under the 2025 ATM Sales Agreement, including sales in excess of the $10 million per calendar year permitted under the Amended SPA, as constituting Permitted ATM Sales and not Prohibited Transactions (each as defined in the Amended SPA). With respect to such past or future sales under the 2025 ATM Sales Agreement, Lind also waived (i) its remedies under the Prohibited Transactions covenant and the Event of Default remedies provisions of the Amended SPA and of each of the 2025 Lind Note and the 2026 Lind Note, including any right to declare amounts due and payable, demand immediate payment in full, accelerate or increase obligations or foreclose upon collateral, (ii) any existing or future Events of Default arising from covenant breaches resulting from such sales, as well as any breach of the notice provision of the Amended SPA to the extent of the Company’s failure to provide timely notice of sales in excess of the annual limit prior to the date of the September 2026 Waiver, and (iii) any adjustment to the Conversion Price of the Lind Notes and the exercise price of the 2025 Lind Warrant and the 2026 Lind Warrant arising out of or in connection with sales under the 2025 ATM Sales Agreement occurring after August 28, 2026. In connection with the September 2026 Waiver, the Conversion Price of the Lind Notes and the exercise price of the warrants were adjusted in accordance with their respective terms for sales under the 2025 ATM Sales Agreement through August 28, 2026.
On September 11, 2026, pursuant to the prepayment provisions of the 2025 Lind Note, the Company prepaid in cash the outstanding principal amount of the 2025 Lind Note in the aggregate amount of approximately $
g) Other Commitments
Belgian Volition
In connection with the acquisition of the Company’s former subsidiary, Volition Germany GmbH, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing. Volition Germany has been dissolved and its assets transferred to Belgian Volition.
As of September 30, 2026, $
VolitionRx
On February 5, 2026, the Company entered into a nine-month loan agreement with First Insurance Funding for a maximum of $
h) Legal Proceedings
In the ordinary course of business, the Company may be subject to claims, counter-claims, lawsuits and other litigation of the type that generally arise from the conduct of its business. The Company is not aware of any legal proceedings that the Company believes would reasonably be expected to have a material adverse effect on its financial position, results of operations, or cash flows.
| 44 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 - Commitments and Contingencies (continued)
i) Commitments in Respect of Corporate Goals and Performance-Based Awards
As of September 30, 2026, the Company had recognized total compensation expense of $
Total |
|
|
| Amortized |
|
| Amortized |
|
| Amortized |
|
| Amortized |
|
| Un-Amortized |
| |||||||
Award |
|
| Vesting |
| 2026 |
|
| 2025 |
|
| 2024 |
|
| 2023 |
|
| 2026 |
| ||||||
$ |
|
| Year |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Effective March 17, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the granting of cash bonuses of up to two months’ gross salary to the salaried employees of the Company and its affiliates, payable upon achievement of various corporate goals focused around licensing, revenue, cost reduction and non-dilutive funding. Pursuant to the terms of the grants, conditioned upon the achievement by the Company or its affiliates/subsidiaries of one or more of the specified corporate goals as set forth in the minutes of the Compensation Committee, and providing that the bonus recipients commenced employment prior to October 1, 2025 and continued employment until at least December 31, 2025, at the sole discretion of both the Chief Executive Officer and the Chief Financial Officer, the Company would accrue a cash bonus to such award recipients, but would defer payment until conditions improved.
Effective March 17, 2025, the Compensation Committee of the Board of Directors approved the granting of RSUs of
As of September 30, 2026, the Company had recognized total compensation expense of $
Total |
|
|
| Amortized |
|
| Amortized |
|
| Un-Amortized |
|
| Cancelled |
| ||||||
Award |
|
| Vesting |
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| |||||
$ |
|
| Year |
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| 45 |
| Table of Contents |
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 9 - Subsequent Events
RSUs Granted
Effective October 21, 2026, the Company granted aggregate RSUs of
RSUs Cancellations
On October 2, 2026,
On October 10, 2026,
On October 10, 2026,
On October 19, 2026,
RSUs Accelerated Vesting
On October 21, 2026, The Company has accelerated a portion of the RSUs granted on February 26, 2026 to an employee. The Company will deem that
Shares Issued in Repayment and Conversion of Convertible Notes
On October 6, 2026, the Company issued an aggregate of
Partial Prepayment of 2026 Lind Note
On October 23, 2026, the Company and Lind entered into a waiver and consent (the “ October 2026 Waiver”) pursuant to which (i) Lind agreed to accept a partial prepayment of outstanding principal by the Company in the amount of $
2025 ATM Sales Agreement
During the period from October 1, 2026 through November 5, 2026, the Company sold
Amendment to Still Independent Director Agreement
On November 4, 2026, the Company and Mr. Timothy Still, Chairman of the Board of Directors, entered into a variation letter effective November 1, 2026 (the “Still Amendment”) to the existing independent director agreement between the Company and Mr. Still dated November 6, 2024 (the “Still Director Agreement”), pursuant to which
Amendment to Reynolds Employment Agreement
On November 10, 2026, Singapore Volition Pte. Limited (“Singapore Volition”) and Mr. Cameron Reynolds, Chief Executive Officer and President of the Company, entered into a variation letter effective November 1, 2026 (the “Reynolds Amendment”) to the existing employment agreement between Singapore Volition and Mr. Reynolds dated March 13, 2023 (the “Reynolds Employment Agreement”), pursuant to which Mr. Reynolds agreed to a further temporary reduction in his annual base salary as part of the Company’s overall cost reduction measures.
END NOTES TO FINANCIALS
| 46 |
| Table of Contents |
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Report and in our Annual Report. This discussion and analysis contains forward-looking statements that are based on our current expectations and reflect our plans, estimates and anticipated future financial performance. These statements involve numerous risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those set forth in the section entitled “Risk Factors” in this Report and in our Annual Report, as well as our other public filings with the SEC. Please refer to the section of this Report entitled “Cautionary Note Regarding Forward-Looking Statements” for additional information.
Overview
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That is the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.
Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors such as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment.
The tests offered by Volition and its subsidiaries are designed to detect and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.
We have several key pillars of focus:
| · | Nu.Q® Vet - cost-effective, easy-to-use blood tests for dogs and other companion animals. The Nu.Q® Vet Cancer Test is commercially available as a cancer screening test in dogs. |
| · | Nu.Q® NETs - detects diseases associated with NETosis such as sepsis. |
| · | Nu.Q® Discover - a complete solution to profiling nucleosomes. |
| · | Nu.Q® Cancer - from screening, diagnosis and staging, therapy decision, planning and treatment to monitoring response to treatment and disease progression with a particular focus on lung cancer. |
| · | Capture-Seq™/ Capture-PCR™ - isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. |
Commercialization Strategy
We are guided by three underlying principles to our commercialization strategy – ensuring our products:
| · | Result in low capital expenditures for licensors and end users and low operating expenses for Volition; |
| · | Are affordable; and |
| · | Are accessible worldwide. |
The principles above inform our overall commercialization strategy for our products, which is driven by the following:
| · | Conducting research and development in-house and through our research partners; |
| · | Monetizing our intellectual property with upfront payments, milestone payments, royalties, and sales of kits and key components; and |
| · | Commercializing our products via global players and in fragmented markets through regional companies. |
There are several routes to market, including (1) licensing, (2) leveraging our existing CE-marked Nu.Q® NETs test, and (3) rolling out the Nu.Q® Lung cancer test:
| 1. Licensing |
We are partnering with established diagnostic companies and liquid biopsy companies to develop, market, sell, and process our tests, leveraging their networks and expertise. In the human space we have agreements with Sysmex, Werfen, Hologic and Revvity. In the veterinary space, we have agreements with Antech, IDEXX and Fujifilm Vet Systems, as well as a number of country-specific distributors.
| 47 |
| Table of Contents |
We believe that, given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, subject to clinical validation, regulatory authorization, and successful commercialization, our tests have the potential for use in markets worldwide.
We aim to remain an intellectual property powerhouse in the epigenetic space and expect to monetize our IP and technologies through licensing and distribution contracts with companies that have established distribution networks and expertise on a worldwide or regional basis, in both human and animal care across platforms (centralized labs and point-of-care / in-house diagnostics).
Human
In September 2025, we signed a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome, or (“APS”), with Werfen, a global leader in the field of specialized diagnostics for hemostasis, thrombosis and other NETs-related indications. The full terms of the agreement are confidential, however, under the agreement, Werfen will gain access to the components of Volition's proprietary Nu.Q® H3.1 NETs assay and will investigate its clinical utility on its platforms in the management of APS patients. Werfen also has an option to negotiate terms with Volition for an exclusive license to commercialize the product.
Also in September 2025, Volition signed an agreement with Hologic Diagenode (NASDAQ: HOLX) or Hologic, for the co-marketing of Volition's Nu.Q® Discover service. Under the agreement, Hologic will co-market Nu.Q® Discover services to Hologic customers for an initial one-year term. If successful, the aim is for Hologic to be appointed as an exclusive provider of those services, subject to further agreed upon terms. The intention of this agreement is to expand customer access to our proprietary Nu.Q® Discover assays.
We are in various stages of active discussions with approximately ten leading diagnostics and liquid biopsy companies for both Nu.Q® and Capture-Seq™, including ongoing technology evaluations, however, there is no guarantee such discussions will result in executed agreements.
Veterinary
On March 28, 2022, we entered into a master license and product supply agreement with Heska, now an Antech Company. In exchange for granting Heska exclusive worldwide rights to sell our Nu.Q® Vet Cancer Test at the point of care for companion animals, Volition received a $10.0 million upfront payment upon signing and a $13.0 million payment based on the achievement of two milestones. Volition is eligible to receive up to an additional $5.0 million upon the achievement of a final milestone, which will occur on the earlier of: (i) the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines, or (ii) the nine-month anniversary of the first peer-reviewed paper evidencing clinical utility for the screening or monitoring of lymphoma in felines being published in any of the periodicals identified by the parties. In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q® Vet Cancer Test in kit format for companion animals through Heska’s network of central reference laboratories.
In October 2022, we entered into a licensing and supply agreement with IDEXX. This contract provides worldwide customer reach through IDEXX’s global reference laboratory network as we continue to commercialize our transformational Nu.Q® technology within the companion animal healthcare sector and capitalize on the significant opportunities available. IDEXX launched the IDEXX Nu.Q® Canine Cancer Test in January 2023.
In November 2023, we launched the Nu.Q® Vet Cancer Test in the UK and Ireland through our distributors, the Veterinary Pathology Group and Nationwide Laboratories. In July 2024, we launched the Nu.Q® Vet Cancer Test in Japan with Fujifilm Vet Systems. As of September 30, 2026, the Nu.Q® Vet Cancer Test is available in over twenty countries.
In March 2025, we signed the first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems to include Volition's ChLIA version of the test via the Immunodiagnostic Systems or IDS i10® automated analyzer platform, for a five year initial term. Fujifilm Vet Systems is expected to be among the first in the world to utilize this centralized lab automation for the Nu.Q® Vet Cancer Test which will enable a more rapid turnaround and high throughput to meet increasing demands.
| 48 |
| Table of Contents |
| 2. Leverage our existing CE-marked Nu.Q® NETs test |
The second prong of our strategy is to leverage our granted CE mark, which has been approved in the EU for any NETs related diseases. Our ChLIA version of the CE-marked Nu.Q® NETs Test is via the IDS-i10™ automated analyzer platform from Immunodiagnostic Systems, a subsidiary of Revvity. Our aim is to sell this product, either directly or in conjunction with Immunodiagnostic Systems, to institutions for use in a wide range of clinical applications where NETosis plays a critical role. In a significant commercial milestone, we recorded our first revenue from sales of our CE-Marked Nu.Q® NETs automated product in Europe in the first quarter of 2025. This is the first revenue generated from a regulated clinically approved product. As of September 30, 2026, we have 12 hospital clients evaluating our Nu.Q® NETs test for a range of diseases.
| 3. Roll-out the Nu.Q® Lung Cancer test |
In the November 2025, we received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer and in January 2026 were delighted to announce that preparation of the reimbursement submission is underway, actively supported by the Hospices Civils de Lyon, France's second largest university hospital system and two other French institutions. Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France in the first half of 2027.
Liquidity and Capital Resources
We have financed our operations since inception primarily through private placements and public offerings of our common stock. As of September 30, 2026, we had cash and cash equivalents of approximately $2.4 million. During the three-months ended September 30, 2026, the Company settled the 2025 Lind Note in full through the issuance of shares of common stock and a final cash payment of $421,754 on September 11, 2026. As of September 30, 2026, $1,516,667 of principal remained outstanding under the 2026 Lind Note.
Net cash used in operating activities was $15.0 million for the nine-months ended September 30, 2026 and $14.2 million for the nine-months ended September 30, 2025, respectively. The increase in cash used in operating activities for the period ended September 30, 2026 when compared to the same period in 2025 can mainly be attributed to a reduction in current liabilities.
Net cash used in investing activities was $0.1 million and $0.1 million for the nine-months ended September 30, 2026 and September 30, 2025, respectively.
Net cash provided by financing activities was $16.9 million for the nine-months ended September 30, 2026 and net cash provided by financing activities was $10.9 million for the nine-months ended September 30, 2025. The increase in cash provided by financing activities for the period ended September 30, 2026 when compared to the same period in 2025 is primarily a reflection of the:
(i) | $1.9 million in cash received, before deducting offering expenses of $0.1 million, from the issuance and sale of shares of common stock and warrants in a senior secured convertible note that closed in January 2026, |
(ii) | $4.6 million in cash raised through Maxim, before deducting offering expenses of $0.3 million, from the issuance and sale of shares of common stock, warrants, and pre-funded warrants in an offering that closed in June 2026, and |
(iii) | $11.8 million in net cash received from the issuance of shares of common stock under our “at-the-market” facility during the period ended September 30, 2026. |
As compared to the following in December 31, 2025
(i) | $2.4 million in cash, before deducting offering expenses of $0.1 million from the issuance and sale of shares of common stock and warrants in a registered direct offering that closed in March 2025 (the “March 2025 RDO”), |
(ii) | $6.3 million in cash, before deducting commitment and legal fees of $0.3 million, received in exchange for the issuance of a senior secured convertible note in May 2025, |
(iii) | $0.3 million in net proceeds, received from the issuance and sale of 448,706 shares of common stock under our “at-the-market” facility with Jefferies LLC acting as exclusive placement agent, |
(iv) | $0.2 million in net proceeds received from the issuance and sale of 321,562 shares of common stock under our Capital On DemandTM Sales Agreement (the “2025 ATM Sales Agreement”) with JonesTrading Institutional Services, LLC (“JonesTrading”) during the nine-months ended September 30, 2025, and |
(v) | $0.3 million in net cash received from the issuance of shares of common stock under our “at-the-market” facility with JonesTrading during the nine-months ended September 30, 2025. |
For additional information on our “at the market facility,” and the March 2025 RDO, refer to Note 6, Common Stock – Equity Distribution Agreement and – 2025 Equity Capital Raise, of the notes to the condensed consolidated financial statements included within this Report.
| 49 |
| Table of Contents |
The following table summarizes our approximate contractual payments due by year as of September 30, 2026.
Approximate Payments (Including Interest) Due by Year | ||||||||||||||||
|
| Total |
|
| 2026 |
|
| 2027 - 2030 |
|
| Greater than 5 years |
| ||||
Description |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Financing lease liabilities |
|
| 327,934 |
|
|
| - |
|
|
| 244,055 |
|
|
| 83,879 |
|
Operating lease liabilities and short-term lease |
|
| 296,610 |
|
|
| 57,649 |
|
|
| 238,961 |
|
|
| - |
|
Grants repayable |
|
| 485,271 |
|
|
| 28,270 |
|
|
| 328,105 |
|
|
| 128,896 |
|
Long-term debt |
|
| 8,168,599 |
|
|
| 804,129 |
|
|
| 6,693,939 |
|
|
| 670,531 |
|
Collaborative agreements obligations |
|
| 1,103,364 |
|
|
| 1,103,364 |
|
|
| - |
|
|
| - |
|
Convertible Notes |
|
| 1,516,667 |
|
|
| 400,000 |
|
|
| 1,116,667 |
|
|
| - |
|
Total |
|
| 11,898,445 |
|
|
| 2,393,412 |
|
|
| 8,621,727 |
|
|
| 883,306 |
|
We intend to use our cash reserves to predominantly fund long term debt, lease liabilities, and commercialization activities. We do not have any substantial source of revenues and expect to rely on additional future financing, through the sale of licensing or distribution rights, grant funding and the sale of equity or debt securities to provide sufficient funding to execute our strategic plan. There is no assurance that we will be successful in raising further funds.
In the event additional financing is delayed, we will prioritize the completion of clinical validation studies for the purpose of the sale of licensing or distribution rights, and the maintenance of our patent rights. In the event of an ongoing lack of financing, it may be necessary to discontinue operations, which will adversely affect the value of our common stock.
We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors included in their report on our audited financial statements for the year ended December 31, 2025, an explanatory paragraph regarding factors that raise substantial doubt that we will be able to continue as a going concern.
For additional information regarding our going concern assessment, refer to Note 2, Liquidity and Going Concern Assessment, of the notes to the condensed consolidated financial statements included within this Report.
| 50 |
| Table of Contents |
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and September 30, 2025
The following table sets forth our results of operations for the three-months ended September 30, 2026 and September 30, 2025.
|
| Three Months Ended September 30, |
|
|
|
|
| |||||||||
|
| 2026 |
|
| 2025 |
|
| Change |
|
| Change |
| ||||
|
| $ |
|
| $ |
|
| $ |
|
| % |
| ||||
Services |
|
| - |
|
|
| 88,896 |
|
|
| (88,896 | ) |
| (<100) | % | |
Product |
|
| 1,613,876 |
|
|
| 538,381 |
|
|
| 1,075,495 |
|
| >100 | % | |
Total Revenues |
|
| 1,613,876 |
|
|
| 627,277 |
|
|
| 986,599 |
|
|
| 157 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
| 1,989,609 |
|
|
| 2,285,907 |
|
|
| (296,298 | ) |
| (13) | % | |
General and administrative |
|
| 2,381,674 |
|
|
| 2,483,793 |
|
|
| (102,119 | ) |
| (4) | % | |
Sales and marketing |
|
| 576,730 |
|
|
| 958,567 |
|
|
| (381,837 | ) |
| (40) | % | |
Total Operating Expenses |
|
| 4,948,013 |
|
|
| 5,728,267 |
|
|
| (780,254 | ) |
| (14) | % | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Loss |
|
| (3,334,371 | ) |
|
| (5,100,990 | ) |
|
| 1,766,619 |
|
| (35) | % | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant income (loss) |
|
| 28,685 |
|
|
| 232,184 |
|
|
| (203,499 | ) |
| (88) | % | |
Gain on disposal of fixed assets |
|
| 260 |
|
|
| - |
|
|
| 260 |
|
| >100 | % | |
Interest income |
|
| - |
|
|
| 160 |
|
|
| (160 | ) |
| (<100) | % | |
Interest expense |
|
| (142,816 | ) |
|
| (143,800 | ) |
|
| 984 |
|
| (1) | % | |
Amortization of debt discount |
|
| (324,480 | ) |
|
| (729,630 | ) |
|
| 405,150 |
|
| (56) | % | |
Gain (loss) on change in fair value of derivative liability |
|
| 198,900 |
|
|
| 304,443 |
|
|
| (105,543 | ) |
| (35) | % | |
Gain (loss) on change in fair value of warrant liability |
|
| 6,400 |
|
|
| 27,842 |
|
|
| (21,442 | ) |
| (77) | % | |
Loss on extinguishment of debt |
|
| (240,201 | ) |
|
| - |
|
|
| (216,801 | ) |
| (<100) | % | |
Total Other Expenses |
|
| (473,252 | ) |
|
| (308,801 | ) |
|
| (141,051 | ) |
|
| 46 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
| (3,807,389 | ) |
|
| (5,409,791 | ) |
|
| 1,602,402 |
|
| (30) | % | |
Revenues
Our operations are transitioning from a research and development stage to a commercialization stage. Revenues during the three-months ended September 30, 2026 were $1.6 million, compared with $0.6 million for the three-months ended September 30, 2025. The main source of revenue during the three-months ended September 30, 2026 and September 30, 2025 was product revenues from sales of the Nu.Q® Vet Cancer Test and the Nu.Q® Discover kits. The year-over-year increase can be attributed to an increase in deferred revenue recognition for the Nu.Q® Vet Cancer Test related to our agreement with Heska. This resulted from a catch-up of deferred revenue recognition of approximately $1.5 million in the three-months period ended September 30, 2026, reflecting an updated forecast in line with our accounting policy. Services revenue relates solely to Nu.Q® Discover services for which revenue recognition is dependent on client project delivery schedules.
Operating Expenses
Total operating expenses decreased to $4.9 million for the three-months ended September 30, 2026 from $5.7 million for the three-months ended September 30, 2025, as a result of the factors described below.
| 51 |
| Table of Contents |
Research and Development Expenses
Research and development expenses decreased to $2.0 million from $2.3 million for the three-months ended September 30, 2026, and September 30, 2025, respectively. This decrease was primarily related to reduced personnel expenses due to headcount reductions and lower stock-based compensation. The number of full-time equivalent (“FTE”) personnel we employed in this division decreased by 13 to 34 compared to the prior year period.
|
| Three Months Ended September 30, |
|
|
| |||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Personnel expenses |
|
| 1,097,882 |
|
|
| 1,292,755 |
|
|
| (194,873 | ) |
Stock-based compensation |
|
| (15,730 | ) |
|
| 52,440 |
|
|
| (68,170 | ) |
Direct research and development expenses |
|
| 454,237 |
|
|
| 488,335 |
|
|
| (34,098 | ) |
Other research and development |
|
| 248,103 |
|
|
| 188,776 |
|
|
| 59,327 |
|
Depreciation and amortization |
|
| 205,117 |
|
|
| 263,601 |
|
|
| (58,484 | ) |
Total research and development expenses |
|
| 1,989,609 |
|
|
| 2,285,907 |
|
|
| (296,298 | ) |
General and Administrative Expenses
General and administrative expenses decreased to $2.4 million from $2.5 million for the three-months ended September 30, 2026, and September 30, 2025, respectively. The reduction was due to lower personnel expenses partly from reduced headcount together with reduced stock-based compensation, partially offset by higher legal and professional fees and general administrative costs during the period. The FTE personnel number within this division decreased by 5 to 12 compared to the prior year period.
|
| Three Months Ended September 30, |
|
|
| |||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Personnel expenses |
|
| 865,636 |
|
|
| 1,102,526 |
|
|
| (236,890 | ) |
Stock-based compensation |
|
| 162,822 |
|
|
| 425,220 |
|
|
| (262,398 | ) |
Legal and professional fees |
|
| 991,251 |
|
|
| 790,894 |
|
|
| 200,357 |
|
Other general and administrative |
|
| 331,725 |
|
|
| 125,788 |
|
|
| 205,937 |
|
Depreciation and amortization |
|
| 30,240 |
|
|
| 39,365 |
|
|
| (9,125 | ) |
Total general and administrative expenses |
|
| 2,381,674 |
|
|
| 2,483,793 |
|
|
| (102,119 | ) |
Sales and Marketing Expenses
Sales and marketing expenses decreased to $0.6 million from $1.0 million for the three-months ended September 30, 2026, and September 30, 2025, respectively. The decrease was primarily due to lower personnel expenses mainly from reduced headcount together with reduced stock-based compensation and direct marketing and professional fees. The FTE personnel number within this division decreased by 3 to 8 compared to the prior year period.
|
| Three Months Ended September 30, |
|
|
| |||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Personnel expenses |
|
| 439,236 |
|
|
| 607,553 |
|
|
| (168,317 | ) |
Stock-based compensation |
|
| 39,856 |
|
|
| 131,507 |
|
|
| (91,651 | ) |
Direct marketing and professional fees |
|
| 96,328 |
|
|
| 213,364 |
|
|
| (117,036 | ) |
Depreciation and amortization |
|
| 1,310 |
|
|
| 6,143 |
|
|
| (4,833 | ) |
Total sales and marketing expenses |
|
| 576,730 |
|
|
| 958,567 |
|
|
| (381,837 | ) |
| 52 |
| Table of Contents |
Operating Loss
For the three-months ended September 30, 2026, the Company’s operating loss was $3.3 million, a reduction of approximately $1.8 million or 35% in comparison to an operating loss of $5.1 million for the three-months ended September 30, 2025. The improved performance compared to the prior year comparative was the result of the increase in revenue by approximately $1.0 million, and a reduction in operating expenses by approximately $0.8 million which mainly reflected lower headcount as a result of actions taken to reduce costs.
Other Expenses
For the three-months ended September 30, 2026, the Company’s other expense was $0.5 million compared to $0.3 million for the three-months ended September 30, 2025. This increase in other expenses reflected non-cash accounting charges related to certain convertible notes issued to Lind Global Asset Management XII LLC (the “Lind Notes”) for amortization of debt discount and loss on extinguishment of debt, partially offset by a gain on change in fair value of derivative liability, during the three-months period ended September 30, 2026.
Net Loss
For the three-months ended September 30, 2026, the Company’s net loss was $3.8 million, a decrease of approximately $1.6 million in comparison to a net loss of $5.4 million for the three-months ended September 30, 2025. The change was a result of the factors described above.
| 53 |
| Table of Contents |
Comparison of the Nine Months Ended September 30, 2026 and September 30, 2025
The following table sets forth our results of operations for the nine-months ended September 30, 2026 and September 30, 2025:
|
| Nine Months Ended September 30, |
|
|
|
|
| |||||||||
|
| 2026 |
|
| 2025 |
|
| Change |
|
| Change |
| ||||
|
| $ |
|
| $ |
|
| $ |
|
| % |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Services |
|
| 58,949 |
|
|
| 366,150 |
|
|
| (307,201 | ) |
| (84) | % | |
Product |
|
| 2,938,660 |
|
|
| 914,200 |
|
|
| 2,024,460 |
|
| >100 | % | |
Total Revenues |
|
| 2,997,609 |
|
|
| 1,280,350 |
|
|
| 1,717,259 |
|
| >100 | % | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
| 6,642,516 |
|
|
| 7,613,228 |
|
|
| (970,712 | ) |
| (13) | % | |
General and administrative |
|
| 7,239,957 |
|
|
| 7,667,909 |
|
|
| (427,952 | ) |
| (6) | % | |
Sales and marketing |
|
| 1,976,944 |
|
|
| 2,919,400 |
|
|
| (942,456 | ) |
| (32) | % | |
Total Operating Expenses |
|
| 15,859,417 |
|
|
| 18,200,537 |
|
|
| (2,341,120 | ) |
| (13) | % | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Loss |
|
| (12,861,808 | ) |
|
| (16,920,187 | ) |
|
| 4,058,379 |
|
| (24) | % | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant income |
|
| 103,302 |
|
|
| 429,411 |
|
|
| (326,109 | ) |
| (76) | % | |
Gain on disposal of fixed assets |
|
| 2,361 |
|
|
| 330 |
|
|
| 2,031 |
| >100 | % | ||
Interest income |
|
| 179 |
|
|
| 478 |
|
|
| (299 | ) |
| (63) | % | |
Interest expense |
|
| (1,009,046 | ) |
|
| (363,825 | ) |
|
| (645,221 | ) |
| (<100) | % | |
Amortization of debt discount |
|
| (1,179,682 | ) |
|
| (1,054,935 | ) |
|
| (124,747 | ) |
|
| 12 | % |
Gain (loss) on change in fair value of derivative liability |
|
| (1,078,858 | ) |
|
| 723,124 |
|
|
| (1,801,982 | ) |
| (<100) | % | |
Gain (loss) on change in fair value of warrant liability |
|
| 20,978 |
|
|
| (14,884 | ) |
|
| 35,862 |
|
| (<100) | % | |
Loss on extinguishment of debt |
|
| (1,823,635 | ) |
|
| - |
|
|
| (1,823,635 | ) |
| (<100) | % | |
Total Other Income (Expenses) |
|
| (4,964,401 | ) |
|
| (280,301 | ) |
|
| (4,684,100 | ) |
| (<100) | % | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
| (17,826,209 | ) |
|
| (17,200,488 | ) |
|
| (625,721 | ) |
|
| 4 | % |
Revenues
Our operations are transitioning from a research and development stage to a commercialization stage. Revenues during the nine-months ended September 30, 2026 were $3.0 million, compared with $1.3 million for the nine-months ended September 30, 2025. Our main source of revenue during the nine-months ended September 30, 2026 and nine-months ended September 30, 2025 was product revenues from sales of the Nu.Q® Vet Cancer Test and the Nu.Q® Discover kits. The year-over-year increase can be attributed to increased product sales and an increase in deferred revenue recognition for the Nu.Q® Vet Cancer Test related to our agreement with Heska. This resulted from a catch-up of deferred revenue recognition of approximately $2.2 million in the nine-months period, reflecting an updated forecast in line with our accounting policy. Services revenue was lower compared to the prior year period and related solely to Nu.Q® Discover services which is highly dependent on client project delivery schedules.
Operating Expenses
Total operating expenses decreased to $15.9 million from $18.2 million for the nine-months ended September 30, 2026 and September 30, 2025, respectively, as a result of the factors described below.
| 54 |
| Table of Contents |
Research and Development Expenses
Research and development expenses decreased to $6.6 million for the nine-months ended September 30, 2026, from $7.6 million for the nine-months ended September 30, 2025. This decrease was primarily related to lower personnel expenses due to reduced headcount together with the release of bonus provisions and reduced stock-based compensation This was partially offset by increased direct research and development expenses. The FTE personnel number decreased by 13 to 34 compared to the prior year period.
|
| Nine Months Ended September 30, |
|
|
| |||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Personnel expenses |
|
| 3,640,346 |
|
|
| 4,506,754 |
|
|
| (866,408 | ) |
Stock-based compensation |
|
| 7,956 |
|
|
| 177,248 |
|
|
| (169,292 | ) |
Direct research and development expenses |
|
| 1,748,234 |
|
|
| 1,542,583 |
|
|
| 205,651 |
|
Other research and development |
|
| 601,961 |
|
|
| 601,746 |
|
|
| 215 |
|
Depreciation and amortization |
|
| 644,019 |
|
|
| 784,897 |
|
|
| (140,878 | ) |
Total research and development expenses |
|
| 6,642,516 |
|
|
| 7,613,228 |
|
|
| (970,712 | ) |
General and Administrative Expenses
General and administrative expenses decreased to $7.2 million from $7.7 million for the nine-months ended September 30, 2026 and September 30, 2025, respectively. The reduction was due to lower personnel expenses partly from reduced headcount together with the release of bonus provisions and reduced stock-based compensation, partially offset by legal and professional fees and other general costs during the period. The FTE personnel number decreased by 5 to 12 compared to the prior year period.
|
| Nine Months Ended September 30, |
|
|
| |||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Personnel expenses |
|
| 2,353,440 |
|
|
| 3,433,045 |
|
|
| (1,079,605 | ) |
Stock-based compensation |
|
| 516,054 |
|
|
| 1,363,968 |
|
|
| (847,914 | ) |
Legal and professional fees |
|
| 3,085,639 |
|
|
| 2,107,465 |
|
|
| 978,174 |
|
Other general and administrative |
|
| 1,188,313 |
|
|
| 646,599 |
|
|
| 541,714 |
|
Depreciation and amortization |
|
| 96,511 |
|
|
| 116,832 |
|
|
| (20,321 | ) |
Total general and administrative expenses |
|
| 7,239,957 |
|
|
| 7,667,909 |
|
|
| (427,952 | ) |
Sales and Marketing Expenses
Sales and marketing expenses decreased to $2.0 million compared to $2.9 million for the nine-months ended September 30, 2026 and September 30, 2025. The reduction was due to lower personnel expenses partly from reduced headcount together with the release of bonus provisions and reduced stock-based compensation. The FTE personnel number decreased by 3 to 8 compared to the prior year period.
|
| Nine Months Ended September 30, |
|
|
| |||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Personnel expenses |
|
| 1,430,699 |
|
|
| 2,078,947 |
|
|
| (648,248 | ) |
Stock-based compensation |
|
| 125,923 |
|
|
| 331,371 |
|
|
| (205,448 | ) |
Direct marketing and professional fees |
|
| 413,519 |
|
|
| 484,297 |
|
|
| (70,778 | ) |
Depreciation and amortization |
|
| 6,803 |
|
|
| 24,785 |
|
|
| (17,982 | ) |
Total sales and marketing expenses |
|
| 1,976,944 |
|
|
| 2,919,400 |
|
|
| (942,456 | ) |
| 55 |
| Table of Contents |
Operating Loss
For the nine-months ended September 30, 2026, the Company’s operating loss was approximately $12.9 million in comparison to an operating loss of $16.9 million for the nine-months ended September 30, 2025. The improved result was the result of the higher revenues, up 134% over prior year, and the reduction in operating expenses down 13% over prior year, which mainly reflected lower headcount as a result of actions taken to reduce costs.
Other Expenses
For the nine-months ended September 30, 2026, the Company’s other expenses were $5.0 million compared to other expenses of $0.3 million for the nine-months ended September 30, 2025. This increase in other expenses primarily reflected non-cash accounting charges related to the Lind Notes for amortization of debt discount, loss on change in fair value of derivative liability, mandatory default amount on convertible notes payable and loss on extinguishment of debt.
Net Loss
For the nine-months ended September 30, 2026, the Company’s net loss was approximately $17.8 million in comparison to a net loss of $17.2 million for the nine-months ended September 30, 2025. The change was a result of the factors described above.
Going Concern
We have not attained profitable operations on an ongoing basis and are dependent upon obtaining external financing to continue to pursue our operational and strategic plans. For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing.
Off-Balance Sheet Arrangements
There have been no material changes to our off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.
Future Financings
We may seek to obtain additional capital through the sale of debt or equity securities if we deem it desirable or necessary. These sales may include the sale of equity securities from time to time through an “at the market offering program” under our Capital On DemandTM Sales Agreement with JonesTrading, refer to Note 6, Common Stock – 2025 ATM Sales Agreement of the notes to the condensed consolidated financial statements included within this Report. However, we may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.
| 56 |
| Table of Contents |
Critical Accounting Policies and Estimates
Our interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles, or GAAP, applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods, which involves a significant level of estimation uncertainty.
We also regularly evaluate estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets, valuations of stock-based compensation, valuation of warrant and derivative liabilities and deferred revenue.
We base our estimates and assumptions on current facts, historical experiences, information from third party professionals and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from our estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.
We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A summary of these policies is included in the notes to our financial statements. There have been no material changes to the critical accounting policies and key estimates and assumptions disclosed in the section titled “Critical Accounting Policies and Estimates” in Part II, Item 7 within our Annual Report.
Recently Issued Accounting Pronouncements
The Company has implemented all applicable new accounting pronouncements that are in effect. The Company does not believe that there are any other applicable new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
| 57 |
| Table of Contents |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company and are not required to disclose this information.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Disclosure controls and procedures are controls and procedures designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, as appropriate to allow timely decisions regarding required disclosure.
Our management carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded, as they previously concluded as of December 31, 2025, that our disclosure controls and procedures were not effective as of September 30, 2026, because of material weaknesses in our internal control over financial reporting, as referenced below and described in detail in our Annual Report.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
We identified a material weakness in our internal controls over financial reporting. In particular we do not have sufficient written documentation of our internal control policies and procedures, including written policies and procedures to ensure the correct application of accounting and financial reporting with respect to the current requirements of GAAP and SEC disclosure requirements.
Notwithstanding the material weakness, we believe that our financial statements contained in this Report fairly present, in all material respects, our financial position, results of operations and cash flows as of and for the periods presented in this Report in accordance with GAAP.
| 58 |
| Table of Contents |
Planned Remediation of Material Weakness
Our management, with the oversight of our audit committee, has initiated steps and plans to take additional measures to remediate the underlying causes of the material weakness, which we currently believe will be primarily through revising precision level management review controls and gaining additional assurance regarding our outside service providers’ quality control procedures. It is possible that we may determine that additional remediation steps will be necessary in the future.
Our management has been actively engaged in developing and implementing remediation plans to address material weakness described above. These remediation efforts are ongoing and include or are expected to include:
| · | We have engaged external consultants to provide support and to assist us in our evaluation of US GAAP; |
| · | Preparation of written documentation of our internal control policies and procedures; and |
| · | Engaging internal control consultants to assist us in performing a financial risk assessment as well as identifying and designing our system of internal controls necessary to mitigate the risks identified; |
We continue to enhance corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility, and accountability to enable remediation of our material weakness. We believe that our remediation plan will be sufficient to remediate the identified material weakness and strengthen our internal control over financial reporting. As we continue to evaluate, and work to improve, our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary.
Changes in Internal Control over Financial Reporting
Except for the ongoing remediation of the material weakness in internal controls over financial reporting noted above, no changes in our internal control over financial reporting were made during the three-months ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations of the Effectiveness of Disclosure Controls and Internal Controls
Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.
The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
| 59 |
| Table of Contents |
PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
In the ordinary course of business, we may be subject to claims, counter claims, lawsuits and other litigation of the type that generally arise from the conduct of our business. We are not aware of any material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our directors, officers or any affiliates, or any registered or beneficial stockholders, are adverse parties or has a material interest adverse to our interest.
ITEM 1A. RISK FACTORS
There have been no material changes in our assessment of risk factors affecting our business since those presented in Part I, Item 1A of our Annual Report.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Recent Sales of Unregistered Securities
In connection with its repayment obligations under the 2025 Lind Note, the Company issued to Lind (i) on July 16, 2026, 372,023 shares of common stock to satisfy a $416,666 payment obligation, (ii) on August 5, 2026, 290,697 shares of common stock upon conversion of $200,000 of principal, (iii) on August 10, 2026, 220,264 shares of common stock upon conversion of $150,000 of principal, (iv) on August 19, 2026, 553,097 shares of common stock upon conversion of $250,000 of principal, (v) on August 26, 2026, 1,232,875 shares of common stock upon conversion of $450,000 of principal, (vi) on August 27, 2026, 3,465,753 shares of common stock upon conversion of $1,265,000 of principal, and (vii) on September 1, 2026, 706,214 shares of common stock upon conversion of $250,000 of principal.
In connection with its repayment obligations under the 2026 Lind Note, the Company issued to Lind (i) on July 14, 2026, 116,651 shares of common stock to satisfy a $133,333 payment obligation, (ii) on September 9, 2026, 707,236 shares of common stock upon conversion of $215,000 of principal, (iii) on September 17, 2026, 698,113 shares of common stock upon conversion of $185,000 of principal, and (iv) on September 22, 2026, 1,459,227 shares of common stock upon conversion of $340,000 of principal. The offering and sale of the shares of common stock underlying the note were made in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The issuance of the shares of common stock was to an existing securityholder, did not involve any paid commissions, did not involve a public offering and was made without general solicitation or general advertising.
Repurchase of Equity Securities
No equity securities were repurchased during the three-months ended September 30, 2026.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
The Company’s directors and officers (as defined in Rule 16a-1 under the Exchange Act) may enter into trading plans or other arrangements with financial institutions to purchase or sell shares of the Company’s common stock. These plans or arrangements may be intended to comply with the affirmative defense provisions of Rule 10b5-1 of the Exchange Act, which are referred to as Rule 10b5-1 trading arrangements, or they may represent non-Rule 10b5-1 trading arrangements.
During the three-months ended September 30, 2026, none of our
| 60 |
| Table of Contents |
ITEM 6. EXHIBITS
|
|
|
| Incorporated by Reference |
|
| ||||||
Exhibit Number |
| Exhibit Description |
| Form |
| File No. |
| Exhibit |
| Filing Date |
| Filed Herewith |
3.1 |
| Second Amended and Restated Certificate of Incorporation, as amended. |
| S-3 |
| 333-288508 |
| 3.1 |
| 7/3/25 |
|
|
3.2 |
| Certificate of Third Amendment of the Second Amended and Restated Certificate of Incorporation. |
| 8-K |
| 001-36833 |
| 3.1 |
| 4/28/26 |
|
|
3.3 |
| Certificate of Fourth Amendment of the Second Amended and Restated Certificate of Incorporation |
| 10-Q |
| 001-36833 |
| 3.3 |
| 8/13/26 |
|
|
3.4 |
| Amended and Restated Bylaws, as amended and currently in effect. |
| 10-Q |
| 001-36833 |
| 3.2 |
| 5/13/24 |
|
|
4.1 |
| Description of Capital Stock. |
|
|
|
|
| 4.2 |
| 07/03/25 |
|
|
10.1 |
| Waiver and Consent, dated September 2, 2026 by and between the Company and Lind Global Asset Management XII LLC |
| 8-K |
| 001-36833 |
| 10.1 |
| 09/02/2026 |
|
|
10.2 |
| Variation Agreement to Independent Director Agreement, dated November 4, 2026, by and between the Company and Timothy Still |
|
|
|
|
|
|
|
|
| X |
10.3 |
| Singapore Volition Pte. Limited Employment Agreement - Group Chief Executive Officer, dated March 13, 2023, as amended February 1, 2026, as further amended November 10, 2026, by and between Singapore Volition and Cameron Reynolds. |
|
|
|
|
|
|
|
|
| X |
31.1* |
| Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
|
|
|
|
|
|
|
|
| X |
31.2 |
| Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
|
|
|
|
|
|
|
|
| X |
32.1* |
| Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
|
|
| X |
101.INS |
| Inline XBRL Instance Document. |
|
|
|
|
|
|
|
|
| X |
101.SCH |
| Inline XBRL Taxonomy Extension Schema Document. |
|
|
|
|
|
|
|
|
| X |
101.CAL |
| Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
|
|
|
|
|
|
|
|
| X |
101.LAB |
| Inline XBRL Taxonomy Extension Label Linkbase Document. |
|
|
|
|
|
|
|
|
| X |
101.PRE |
| Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
|
|
|
|
|
|
|
|
| X |
101.DEF |
| Inline XBRL Taxonomy Extension Definition Linkbase Document. |
|
|
|
|
|
|
|
|
| X |
104 |
| Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
|
|
|
|
|
|
|
|
| X |
* The certifications attached as Exhibit 32.1 accompany this Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.
| 61 |
| Table of Contents |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VOLITIONRX LIMITED | |||
Dated: November 12, 2026 | By: | /s/ Cameron Reynolds | |
|
| Cameron Reynolds | |
| President and Chief Executive Officer | |||
| (Authorized Signatory and Principal Executive Officer) | |||
|
|
|
|
Dated: November 12, 2026 | By: | /s/ Terig Hughes |
|
|
| Terig Hughes |
|
|
| Chief Financial Officer and Treasurer |
|
|
| (Authorized Signatory and Principal Financial and Accounting Officer) |
|
| 62 |